尊龙凯时·[中国]官方网站

- Novel selective T-helper cell inhibitor treats bronchial asthma from the source, reduces airway inflammation, decreases airway hyperresponsiveness, reduces acute asthma attacks, relieves symptoms and improves lung function;

- Reduce hormone dosage and reduce β2 receptor agonists: assist patients with moderate to severe asthma, hormone-dependent/resistant asthma, reduce hormone dosage.

- Good results in patients who do not respond to leukotriene receptor antagonists;

- High safety and suitable for long-term use: It is an adult long-term management medication recommended in Japanese guidelines for adult asthma.